“Latest Stem Cells News”

“For centuries, scientists have known that certain animals can regenerate missing parts of their bodies. Humans actually share this ability with animals like the starfish and the newt. Although we can’t replace a missing leg or a finger, our bodies are constantly regenerating blood, skin, and other tissues.

The identity of the powerful cells that allow us to regenerate some tissues was first revealed when experiments with bone marrow in the 1950s established the existence of stem cells in our bodies and led to the development of bone marrow transplantation, a therapy now widely used in medicine.

This discovery raised hope in the medical potential of regeneration. For the first time in history, it became possible for physicians to regenerate a damaged tissue with a new supply of healthy cells by drawing on the unique ability of stem cells to create many of the body’s specialized cell types (…)”

Read full story clicking here

Incoming search terms:

BioMedReports: There has been some talk about the upcoming opening of your new state-of-the-art facility. Can you tell us about that?

CEO Matthew L. Schissler: We always try to focus on three core goals and in 2010 we are opening our new state of the art laboratory. One of those three core goals is the diversification of revenue streams. Not only will we have our own organic growth engine, by processing and storing for our own company, but we recently entered into a letter of agreement to process and store for another very successful stem cell company. That’s going to be the flavor for 2010 and onward- diversification of revenue streams by using our new facility to its full capacity. The other goal is continued growth- like we saw mention of when we announced in late 2009 when we signed an agreement with a national labor association, Blue Cross and Blue Shield Association. That’s how we’ll grow some more, through the insurance companies. And finally, we’re going to be very focused on acquisitions. In fact, I’ll tell you that in 2010 we have a voracious appetite for acquisitions. With the economy the way it is, a lot of stem cell companies are struggling and we’ve been very fortunate to have our company go in the right direction by reducing debt and raising capital. We feel it’s a very good time for us to make some acquisitions and so we’re going to be very focused on that this year.

BioMedReports: So I would imagine that these acquisitions are somehow related to the goal of increasing your revenue streams in some way?

CEO Matthew L. Schissler: The overall goal in our mission statement is to not only become the world’s number one most respected stem cell company but also to be the largest as well. As we say in our mission statement, the world’s globally dominant stem cell storage company and so, those acquisitions will be in related fields, but I can’t say too much but it’s all about cryogenic preservation of stem cells and other forms of biologics.

Incoming search terms:

Researchers and using stem cells as tools for disease study, drug screening, clinical trial strategy, and personalized medicine. The induced Pluripotent Stem cell (iPS) is giving us a chance to rethink the way we are developing new drugs. These iPS cells are usually created from somatic cells (such as skin), and not embryos or adult stem cells. In creating iPS from patients’ diseased cells, scientists can study the disease in vitro, looking for disease phenotypes, applying microenvironmental stress, and testing new drugs. Compared to animal model testing (e.g. mice), this represents a significant breakthrough, that can be used to validate clinical development strategy and test efficacy in specific groups of patients. iPS is bringing a revolution in drug discovery methodology which is being used to bridge genetics, cell biology, and physiology.

from http://biobusiness.tv/videos/208

Incoming search terms:

SANUWAVE Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

Dr. Myron Spector, PhD, Professor of Orthopaedic Surgery (Biomaterials) at Harvard Medical School, Director of Orthopaedic Research at Brigham and Women’s Hospital and Director of Tissue Engineering at VA Boston Healthcare System, was an invited guest speaker at the Conference. The Bone–Tec Congress featured an international scientific forum to discuss progresses in modern bone tissue regeneration and extended a worldwide network to exchange findings on the latest developments.

Dr. Spector’s team employed SANUWAVE’s Pulsed Acoustic Cellular Expression (PACE™) technology in preclinical research to create autogenous sources of stem cells for bone tissue engineering. Results support the proposition that PACE™ could be employed as a non-invasive technique to cause proliferation and thickening of the cambium layer of the femur’s periosteum for the subsequent intraoperative harvesting of progenitor stem cells days later for bone or cartilage regeneration.

PACE™ stimulated a dramatic proliferation and thickening (up to 10 fold) of osteoprogenitor stem cells, precursors to bone and cartilage cells, in the cambium layer of the periosteum in the femur of the adult rats within 4 days. Neovascularization and new bone formation within the thickened periosteum were also evident after 4 days.

Dr. Spector said, “This research has shown great potential. Through more study, this technology could further advance tissue engineering autologous transplant techniques towards clinical applications such as bone reconstruction and cartilage defect repair.” (…)

from http://www.sanuwave.com

Incoming search terms:

On Sept. 14, 46-year-old Hatem Faraj suffered a major heart attack while watching Monday Night Football on TV.
Tuesday, the Wesley Chapel man joined the cutting edge of heart disease research, becoming the area’s first participant in a study to see if a patient’s own stem cells can regenerate his damaged heart muscle.

The procedure he had at Pepin Heart at University Community Hospital in Tampa is part of a University of Florida research program. Its aim is improving chances of long-term survival and reducing heart transplants. Using stem cells to regenerate heart tissue has been studied for several years in animals and humans, producing mixed results. Still, the therapy is considered promising for millions of Americans with heart failure (…)

The most appealing part of the study is that a patient’s own stem cells are used, he said. “It won’t hurt you to participate,” Matar said. “I would encourage physicians to refer their patients.”

Researchers are looking at many questions surrounding the therapy: how many stem cells to infuse into the heart, how long it will take to see results, how soon after a cardiac event should treatment be delivered, how much tissue regeneration can patients expect. The long-term effects of such therapy are unknown.

The University of Florida is one of five U.S. medical centers involved in three federally funded stem cell regeneration clinical trials. Bay area hospitals with cardiac care programs were asked help enroll the almost 300 patients needed for the 2 1/2-year-long study.

“It will be a challenge,” says Dr. Charles Lambert, medical director at Pepin, the first satellite center in Florida to recruit a study participant. Lambert says that’s because patients who have just survived a heart attack must undergo two medical procedures: one to harvest bone marrow in order to get the stem cells, and another to infuse cells in the heart.

Two-thirds of participants will be infused with stem cells; the others will receive a cell-free solution. Patients — including Faraj — won’t know if they actually receive stem cells, standard protocol in medical research (…)

Because it was the first procedure at a satellite center, a UF medical team traveled to Tampa to assist with the bone marrow harvest earlier Tuesday and drive the cells back to Gainesville. There, scientists isolated the heart and vascular stem cells, extracted and purified them and handed them off to a second medical team. They drove the little bag of cells, about six tablespoons worth, back to Tampa.

Faraj was only mildly sedated during the hourlong infusion, in which the stem cells (or a cell-free solution) were sent to his heart through a catheter inserted in the groin and threaded through the femoral artery to his heart. He was smiling and talking with hospital staff immediately afterward (…)

from http://www.tampabay.com/news/health/study-hopes-to-use-patients-own-stem-cells-to-mend-broken-hearts/1041081

Incoming search terms:

What might become the first drug derived from human stem cells failed in two late-stage clinical trials, dealing a setback to the drug’s developer and to the stem cell field (…)

Prochymal is a preparation of mesenchymal stem cells, which are obtained from the bone marrow of healthy young adults.
Because the cells are derived from adults, they sidestep the ethical issues stemming from the destruction of human embryos needed to make embryonic stem cells. Unlike most other types of adult stem cells, mesenchymal cells grow well in culture, so thousands of doses can be produced from a single donation.

Stem cells, particularly in the form of bone marrow transplants, are already used in medicine. Osiris is hoping that Prochymal will become the first stem cell product approved by the Food and Drug Administration and sold as a mass-produced pharmaceutical product (…)

from http://www.nytimes.com/2009/09/09/health/research/09drug.html

Incoming search terms: